Anti-Mullerian hormone as an ovarian reserve marker in women with the most frequent muscular dystrophies

Autoři

PARMOVÁ Olesja VLČKOVÁ Eva HULOVÁ Monika MENSOVA Livie CRHA Igor STRÁDALOVÁ Petra KRALICKOVA Eva JUŘÍKOVÁ Lenka PODBORSKÁ Martina MAZANEC Radim DUŠEK Ladislav JARKOVSKÝ Jiří BEDNAŘÍK Josef VOHÁŇKA Stanislav ŠROTOVÁ Iva

Rok publikování 2020
Druh Článek v odborném periodiku
Časopis / Zdroj Medicine
Fakulta / Pracoviště MU

Lékařská fakulta

Citace
www https://journals.lww.com/md-journal/FullText/2020/06050/Anti_M_llerian_hormone_as_an_ovarian_reserve.42.aspx
Doi http://dx.doi.org/10.1097/MD.0000000000020523
Klíčová slova anti-Mullerian hormone; fertility; muscular dystrophy; myotonic dystrophy; ovarian reserve
Popis Some muscular dystrophies may have a negative impact on fertility. A decreased ovarian reserve is 1 of the factors assumed to be involved in fertility impairment. AMH (anti-Mullerian hormone) is currently considered the best measure of ovarian reserve. A total of 21 females with myotonic dystrophy type 1 (MD1), 25 females with myotonic dystrophy type 2 (MD2), 12 females with facioscapulohumeral muscular dystrophy (FSHD), 12 female carriers of Duchenne muscular dystrophy mutations (cDMD) and 86 age-matched healthy controls of reproductive age (range 18 - 44 years) were included in this case control study. An enzymatically amplified 2-site immunoassay was used to measure serum AMH level. The MD1 group shows a significant decrease of AMH values (median 0.7ng/mL; range 0 - 4.9ng/mL) compared with age-matched healthy controls (P<.01). AMH levels were similar between patients and controls in terms of females with MD2 (P=.98), FSHD (P=.55) and cDMD (P=.60). This study suggests decreased ovarian reserve in women with MD1, but not in MD2, FSHD and cDMD.
Související projekty: